Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Inoperable Hepatocellular Carcinoma
NCT00508001Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2007
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Sanofi. Primary endpoint: Tumour Stabilisation Rate at 16 weeks. Started Jul 2007; status: completed.
02
Drugs
vandetanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00508001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508001.